Recent Updates
Recently added Catalysts

Novel restraint

Phase 1

Acute Respiratory Failure | Unknown | Other |Design Therapeutics, Inc.|Last Updated: May 29, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment8
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03621475Novel Arm Restraint in the Intensive Care UnitPHASE1 COMPLETED 8Oct 1, 2018Apr 15, 2019May 29, 20251 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Treatment-Emergent Severe Adverse Events [Safety]
Through study day 2

Safety will be measured by the number (i.e. \< 1 in 5 participants had a treatment emergent safety event per their on study time) across all of the following measures listed below. Incidence does not have to be per person-year; in this case it is incidence of safety adverse event during the study period.

Number of Clinician or Patient Lacerations
Through study day 2

Grade 2b or higher skin laceration (per Skin Tear Audit Research \[STAR\] Skin Tear Classification System) in patient or clinician from any sharp edges of device. The STAR grading system ranges from grade 1a at best to 3 at worst. Each laceration is given an individual score based on appearance.

Number of Pressure Ulcers From Device
Through study day 2

Development of pressure ulcer from device of Stage 3 or greater per 2016 National Pressure Ulcer Advisory Panel Pressure Injury Stages. This staging system provides an individual score to each pressure ulcer based on appearance from stage 1 (best) to stage 4 (worst)

Number of Self-removals of Novel Restraint
Through study day 2

Self-removal of novel restraint

Number of Damaging Events to Hospital Bed Rendering it Non-functional
Through study day 2

Any damage to hospital bed from restraint device rendering it non-functional

Number of Damaging Events to ICU Equipment
Through study day 2

Any damage to ICU equipment (e.g. ventilator) rendering it non-functional

Secondary Endpoints
Number of Self-extubations
Through study day 2
Number of Movements of Upper Extremities
Continuously through study day 2
Richmond Agitation Sedation Score [RASS]
Median of multiple RASS scores collected over first 2 days of study period
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Novel restraint first, then traditional restraintEXPERIMENTALParticipants will be randomized to wear the novel arm restraint bilaterally for 4 hours on study day #1, followed by traditional soft bilateral wrist restraints for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
Traditional restraint first, then novel restraintEXPERIMENTALParticipants will be randomized to wear traditional soft bilateral wrist restraints for 4 hours on study day #1, followed by the novel arm restraint bilaterally for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
Interventions
NameTypeDescription
Novel restraintDEVICEUse of a novel arm restraint
Unlock Study Design Details
Eligibility Criteria
Age Range65 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. \>65 years old 2. Physician order for use of bilateral wrist restraints 3. Requiring mechanical ventilation with actual or expected total duration of \>48 hours 4. Expected ICU stay \>3 days after enrollment (to permit adequate exposure to proposed intervention) 5. Not deeply...

Countries:United States
Unlock Eligibility Criteria